<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651881</url>
  </required_header>
  <id_info>
    <org_study_id>A88_09BE2016P</org_study_id>
    <nct_id>NCT04651881</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in&#xD;
      Healthy Volunteers under fed conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, crossover study to investigate the pharmacokinetic&#xD;
      profiles and safety of high-dose CKD-385 in healthy volunteers under fed conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">December 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to time of CKD-385</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Maximum plasma concentration of CKD-385</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Area under the concentration-time curve from zero up to infinity of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Time to maximum plasma concentration of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Terminal elimination half-life of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Apparent clearance of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of CKD-385</measure>
    <time_frame>Pre-dose (0 h),1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Apparent Volume of Distribution of CKD-385</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference drug&#xD;
Period 2: Test drug 1&#xD;
Period 3: Test drug 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug 2&#xD;
Period 2: Reference drug&#xD;
Period 3: Test drug 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug 1&#xD;
Period 2: Test drug 2&#xD;
Period 3: Reference drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug 2&#xD;
Period 2: Test drug 1&#xD;
Period 3: Reference drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug 1&#xD;
Period 2: Reference drug&#xD;
Period 3: Test drug 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference drug&#xD;
Period 2: Test drug 2&#xD;
Period 3: Test drug 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference drug</intervention_name>
    <description>1 Cap., single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>D744</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug 1</intervention_name>
    <description>1 Tab., single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>CKD-385 64 mg formulation I (878mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug 2</intervention_name>
    <description>1 Tab., single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>CKD-385 64 mg formulation II (878mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult aged more than 19 at the time of screening&#xD;
&#xD;
          2. Those who had 18.0kg/m² ≤ Body Mass Index (BMI) &lt; 30.0kg/m²&#xD;
&#xD;
             # BMI=Weight(kg) / Height(m)²&#xD;
&#xD;
          3. Those who have no congenital diseases or chronic diseases and have no abnormal&#xD;
             symptoms or findings on a medical examination.&#xD;
&#xD;
          4. Those who are eligible for clinical trials based on laboratory (hematology, blood&#xD;
             chemistry, urinalysis, serology), vital signs and ECG results at screening.&#xD;
&#xD;
          5. Those who have voluntarily given written informed consents to participate in the study&#xD;
             and to comply with all the instructions, based on full understanding of the nature of&#xD;
             the study after listening to detailed explanations.&#xD;
&#xD;
          6. Those who agree to double contraception method from the 1st dministration of the&#xD;
             investigational product until 7 days after the last administration of investigational&#xD;
             product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who has medical evidence or history of clinically significant hematological,&#xD;
             renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic,&#xD;
             psychiatric, neurologic or allergic diseases(except for simple dental history such as&#xD;
             tartar, mpacted teeth, wisdom teeth).&#xD;
&#xD;
          2. Those with a medical history of gastrointestinal disorders(esophageal achalasia or&#xD;
             esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple&#xD;
             appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect&#xD;
             the absorption of drug.&#xD;
&#xD;
          3. Those who has a history of regular alcohol consumption in excess of 14 glasses/week&#xD;
             for woman, 21 glasses/week for man within 1 months prior to screening.&#xD;
&#xD;
          4. Those who received investigational products or bioequivalence test drugs within 6&#xD;
             months before the first administration of clinical trial drugs.&#xD;
&#xD;
          5. Those who take drugs which may cause induction or inhibition of drug metabolism within&#xD;
             30 days before the first administration of investigational products.&#xD;
&#xD;
          6. Those who have taken any drugs that may affect the clinical trial within 10 days.&#xD;
&#xD;
          7. Those who donated whole blood within 2 months, or blood components within 2 week&#xD;
             before first administration of investigational products.&#xD;
&#xD;
          8. Those who is unable to consume a high-fat meal provided during the study.&#xD;
&#xD;
          9. Those who are deemed insufficient to participate in this clinical study by&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-gi Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRAL HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Siheung-si</state>
        <zip>15079</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

